Beta-Blocker

Concurrent use of a beta-blocker with Simbrinza delayed the onset of ocular allergy and may extend treatment duration and adherence among patients with glaucoma, according to a retrospective study in BMC Ophthalmology.

In the ABYSS trial, a strategy of interrupting long-term beta-blocker treatment was not noninferior to continued use for the primary composite outcome of death, myocardial infarction, stroke or hospitalization for CV reasons.

Over the last 50 years, revascularization and pharmacotherapeutic innovations have led to significant reductions in major adverse CV events associated with both acute and chronic coronary diseases.

ATLANTA — In patients who underwent early angiography for acute MI and had ejection fraction of 50% or more, long-term beta-blocker use did not reduce risk for death or new MI compared with no use, researchers reported.

Pharmacists are one of the most accessible health care providers and singularly well positioned to lead efforts in integrating pharmacogenomics testing to improve medication-related outcomes.

Use of nonselective beta-blockers was associated with stage 2 acute kidney injury and all-cause mortality among patients with decompensated cirrhosis waitlisted for liver transplantation, data showed.

PHILADELPHIA — An intensive medication optimization program for patients hospitalized with HF with reduced ejection fraction would be cost-effective, researchers reported at the American Heart Association Scientific Sessions.

Results showed use of beta-blockers was associated with a reduced chance of patients undergoing total knee arthroplasty, which could be due to a possible relationship between the autonomic nervous system and progression of osteoarthritis.

Updates on beta-blocker use, revascularization and routine testing and recommendations on healthy lifestyle are among the highlights of a new guideline on the management of patients with chronic coronary disease.

Quadruple therapy after discharge was feasible for a large proportion of patients with HF reduced ejection fraction, yet few were prescribed the “four pillars” of HFrEF therapy, researchers in Italy reported.